Baxdrostat Reduces 24-Hour Blood Pressure in Resistant Hypertension

Resistant hypertension remains a major driver of cardiovascular and renal morbidity, characterized by persistently elevated blood pressure despite adherence to at least three antihypertensive medications, including a diuretic [1]. A key pathophysiological contributor to this hard-to-control phenotype is inappropriate aldosterone production, which promotes fluid retention, vascular dysfunction, and target organ damage [2]. To address this, researchers have developed highly selective aldosterone synthase inhibitors, medications designed to suppress aldosterone production without interfering with cortisol synthesis [3]. While earlier phase 2 trials and meta-analyses have demonstrated the blood pressure-lowering potential of agents like baxdrostat, questions have remained regarding their definitive efficacy and safety profiles in larger, late-stage clinical trials [4, 5]. A newly published phase 3 trial now provides rigorous ambulatory blood pressure data to clarify the clinical utility of targeting aldosterone synthesis in this high-risk patient population.